FDA Approval of Aduhelm Paves a New Path for Alzheimer’s Disease
Rudolph E. Tanzi
Abstract
ADVERTISEMENT RETURN TO ISSUEEditorialNEXTFDA Approval of Aduhelm Paves a New Path for Alzheimer's DiseaseRudolph E. TanziRudolph E. TanziMore by Rudolph E. TanziCite this: ACS Chem. Neurosci. 2021, 12, 15, 2714–2715Publication Date (Web):July 14, 2021Publication History Published online14 July 2021Published inissue 4 August 2021https://pubs.acs.org/doi/10.1021/acschemneuro.1c00394https://doi.org/10.1021/acschemneuro.1c00394editorialACS PublicationsCopyright © 2021 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views5637Altmetric-Citations16LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (475 KB) Get e-AlertscloseSUBJECTS:Central nervous system,Immunotherapy,Nervous system diseases,Peptides and proteins,Pharmaceuticals Get e-Alerts